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ABSTRACT
Objectives: To evaluate the utility of intrapartum amnioinfusion (AI) in reducing the infectious
morbidity of patients with meconium-stained fluid (MSF). Previous studies have shown increased
intraamniotic infection (IAI) and postpartum endometritis (PPE) rates in patients with MSF.
Intraamniotic infection has been reduced with the prophylactic administration of ampicillin-
sulbactam in MSF. Intraamniotic infection and PPE have been reduced with the use of AI in
patients with clear fluid. No investigators have specifically examined the efficacy ofAI in reducing
meconium-stained, amniotic-fluid-associated infectious morbidity.
Methods: A retrospective cohort study of all cases ofMSF was conducted and included patients
who delivered at Louisiana State University Medical Center-Shreveport during the one-year pe-
riod from January to December 1996. Patients were identified from the perinatal database by the
diagnosis code of MSF. The medical records were reviewed to determine the consistency ofMSF
and the presence or absence of infectious morbidity. Patient demographics, labor characteristics,
and various risk factors for infection were sought. The main outcome measures were the occur-
rence of clinical IAI or PPE. Statistical analysis included two-tailed unpaired t-test, X2, ANOVA,
and Fisher exact test when appropriate.
Results: Two hundred seventy-three medical records of patients with MSF were studied. One
hundred twenty nine patients received AI, and 144 did not receive AI. No significant differences in
demographics, labor characteristics, or outcome variables were noted between the two groups. The
incidences of IAI were 18.6% and 24.3%, P 0.13, in the AI and non-AI groups, respectively.
Postpartum endometritis occurred in 22.5% of AI patients and 21.5% of non-AI patients, P 0.97.
Conclusions: The use ofAI confers no benefit for the reduction of infectious morbidity in patients
with MSF. Infect. Dis. Obstet. Gynecol. 5:366-369, 1997. (C) 1998 Wiley-Liss, Inc.
KEY WORDS
mcconium; infectious complications; amn]oinfus]on
econium-stained amniotic fluid (MSF) has
been associated with increased infectious
morbidity.TM This morbidity has been limited to
the mother and is manifested as intraamniotic in-
fection (IAI) and postpartum endometritis (PPE).
Meconium passage is present in up to 500,000
cases annually in the United States. 1, z, 13 When
MSF is present, IAI can occur in as many as 22% of
parturients, and PPE can occur in up to 10% of
cases.4-7 With such frequent occurrences of both
meconium passage and subsequent infectious com-
plications, some 100,000 patients may be affected
annually.
The observed increase in infectious morbidity
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among parturients with MSF may stem from sev-
eral mechanisms that most likely work simulta-
neously. Meconium’s constitutive elements serve
as excellent substrates for bacterial growth, s, 9 It is
composed of sugars, water, bile acids, and nitrogen
compounds; all are required for bacterial growth.
Meconium has also been shown to interfere with
enzyme systems that help to make amniotic fluid
bacteriostatic.lO, 11
Recently, it was shown that the administration
of ampicillin-sulbactam intravenously "at the time
of meconium diagnosis (during the intrapartum pe-
riod) resulted in a significant reduction in IAI and
a trend towards reducing PPE. 14 While this pro-
phylactic protocol effectively reduced infectious
complications, repeated or singular doses of broad-
spectrum antibiotics such as ampicillin-sulbactam
are of concern. Foremost, this policy cotld lead to
a selection of more virulent organisms. Secondly,
an increased cost is incurred with the adoption of
this prophylactic practice.
Amnioinfusion (AI) has been used to treat vari-
able decelerations of the fetal heart rate and to
improve neonatal outcomes in cases complicated
by meconium passage.1-19 Amnioinfusion has also
proven effective for reducing the meconium aspi-
ration syndrome. The success of AI for prevention
of meconium aspiration syndrome may be second-
ary to a dilutional effect. 17 Other investigations
have shown a significant reduction in meconium
concentration when AI is used. Although some in-
vestigators have reported a reduction in infections
among patients who receive AI with clear fluid
(i.e., for treatment of variable decelerations), no
studies have specifically addressed the effect of AI
on infectious complications when there is MSF.z, 21
We designed this retrospective cohort study to
address the utility of AI in cases complicated by
MSF and its infectious complications.
MATERIALS AND METHODS
This retrospective cohort study was performed at
Louisiana State University Medical Center-
Shreveport. All patients identified as having meco-
nium staining between January 1996 and Decem-
ber 1996 served as the basis for this report.
Patients were separated into two groups: those
who received AI and those who did not. Maternal,
obstetric, and labor characteristics were obtained
from the medical records. We sought out clinical
variables associated with an increased risk of IAI
and PPE, specifically, length of labor and rupture
of membranes, induction of labor, epidural anes-
thesia, and vaginal examinations. Patients with evi-
dence of active infection at the time of admission
to labor and delivery were excluded.
Intraamniotic infection was defined as a tem-
perature greater than 100.5F with the presence of
one or more of the following: fetal and/or maternal
tachycardia, uterine tenderness, or foul-smelling
amniotic fluid. Postpartum endometritis was de-
fined as a temperature greater than 100.5F on two
occasions after delivery with the presence of uter-
ine tenderness and/or foul-smelling lochia.
During the study interval we used a risk factor
method for prophylaxis for group B beta hemolytic
streptococcus. This included rupture of mem-
branes ->12 hours, prematurity -<37 weeks, and
urine culture positive for group B streptococcus.
Statistical analysis consisted of two-tailed un-
paired t-test for continuous data. Categorical data
were analyzed by chi-square or Fisher exact test as
appropriate. An a priori sample size was calculated.
Based on our previous work, we predicted a 25%
incidence of infection in the control (non-AI)
group. We assumed that AI would be associated
with a 70% reduction in infectious morbidity.
Given these assumptions, we required a cohort of
260 patients to test our hypothesis with 80% power
and significance set at P =0.05.
During the study period a standard AI protocol
existed. It consisted of one liter of normal saline
warmed to 98.6F. The AI was started with a 600-
ml bolus followed by a constant infusion of 180
ml/h. All patients undergoing cesarean delivery re-
ceived 2.0 g cefazolin (AncefTM, Smith Kline, Phila-
delphia, PA) intravenously at cord clamping.
RESULTS
Two hundred eighty one cases of meconium pas-
sage meeting the criteria were recorded. Two hun-
dred seventy three were available for review. One
hundred twenty nine of these had AI, while 144
did not. Twenty seven patients had evidence of
acute IAI at admission and were not included.
There were no significant maternal demographic,
obstetric, or labor differences between the two
groups (Tables 1-3). The two groups also had simi-
lar rates of PPE and IAI (Table 4). The lone ex-
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TABLE I. Demographics
Amnioinfusion No amnioinfusion
Characteristics (n 129) (n 144) P
Age (years) 24.8 + 5.9 25. + 6.5 NS
Primigravida 43 (33.3%) 39 (27. I%) NS
Para -> 71 (55.0%) 93 (64.6%) NS
Gestational age
(weeks) 39.4 + 1.6 39.2 + 2. NS
Race NS
Black 109 (84.5%) 112 (77.8%)
White 20 (I 5.5%) 32 (22.2%)
aData presented as mean + Standard Deviation or Number (%). NS, not
significant.
ception was an obvious 100% use of intrauterine
pressure catheters in the AI group versus 53.5% in
the non-AI group, P -< 0.001.
DISCUSSION
This study sought to define the possible role of AI
as prophylaxis for infectious complications associ-
ated with MSF. This approach is appealing be-
cause it could potentially reduce significant infec-
tious complications in a cost-effective manner that
would not alter normal flora or select for resistant
organisms. This concept was previously shown to
be valid in cases of clear amniotic fluid, but we
could not confirm the benefit of AI in this retro-
spective study of MSF.z, el
This study does have some limitations. Fore-
most among them is the retrospective study design.
This inherently allows for possible biases and thus
potentially influences the study outcome. We at-
tempted to minimize study bias by limiting the
study period to one continuous year and attempt-
ing to obtain all medical records. We were able to
obtain 97.1% of the records. While this clearly is
less than 100%, we doubt any serious significant
differences would exist in the remaining 2.9% of
charts. Even assuming that all the patients whose
records were missing were among the non-AI group
and that all eight had IAI and PPE, no significant
difference would be detected.
Our findings are similar to those ofMacri et al., 17
who, after a prospective randomized trial of AI ver-
sus no AI for relief of variable decelerations, re-
ported that AI was not associated with a reduction
in infectious complications. However, the effect of
AI on infectious complications was not a primary
outcome variable in this study and their report
lacked the power to definitively rule out a benefi-
TABLE 2. Labor characteristics
Amnioinfusion No amnioinfusion
Characteristic (n 129) (n 144) P
IUPC 129 (I 00%) 77 (53.5%) <0.00
Length of ROM
(minutes) 423.9 + 215.6 399.6 + 235.2 NS
Length of labor
(minutes) 586.4 + 184.3 560.3 + 176.7 NS
AROM 93 (72. I%) 102 (70.8%) NS
FSE III (86.0%) II 8 (81.9%) NS
Epidural 89 (68.9%) 96 (66.7%) NS
Inductions 24 (18.6%) 23 (16.0%) NS
Cesarean delivery 24 (18.6%) 25 (17.4%) NS
Group B
streptococcus
prophylaxis 35 (27. I%) 38 (26.4%) NS
Vaginal
examinations 5.8 + 2.6 5.6 + 2.4 NS
aData presented as mean + Standard Deviation or Number (%). NS, not
significant; IUPC, intrauterine pressure catheter; ROM, rupture of
membranes; AROM, artificial rupture of membranes; FSE, fetal scalp
electrode.
TABLE 3. Meconium consistency
Amnioinfusion No amnioinfusion
Consistency (n 129) (n 144) P 0.67
Thick 63 (48.8%) 72 (50.0%)
Moderate 36 (27.9%) 33 (22.9%)
Thin 30 (23.3%) 39 (27. I%)
Data presented as N (%).
TABLE 4. Main outcome measures
Amnioinfusion No amnioinfusion
Variable (n 129) (n 14)
Intraamniotic 24 (18.6%) 34 (23.6%) 0.13
infection
Postpartum 29 (22.5%) 31 (21.5%) 0.97
endometritis
aData presented as N (%).
cial effect. 17 Our study results are contradictory to
those ofMoen et al. and Monahan et al., who found
that infectious complications were reduced in the
presence of clear amniotic fluid,e, z Thus the
presence of meconium may be too detrimental to
apply a simple approach of "dilution of the pollu-
tion."
We currently are left with the broad-spectrum
intravenous antibiotic ampicillin-sulbactam admin-
istered every six hours as the only proven effective
prophylactic measure. 14 This, we feel, is less than
optimal because of the possible emergence of more
virulent bacteria. We had hoped that AI would be
as effective as ampicillin-sulbactam without its at-
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tendant risks. We currently are investigating the
effects of a single dose of ampicillin-sulbactam in
reducing infectious complications. Perhaps other
efforts could address more narrow-spectrum
agents, such as erythromycin or ampicillin.
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